Career Development Awards will be used to support the development of careers in translational pancreatic cancer research by individuals from one of the following categories: 1) clinical fellows in medical oncology, gastroenterology, pathology, or surgery; 2) junior faculty members at the instructor or assistant professor level, either clinical faculty who seek training and an opportunity to establish a career that includes basic science research, or basic science faculty who want additional training or an opportunity to undertake translational research; 3) senior postdoctoral fellows who are at the point of entering the academic ranks and establishing independent research programs; 4) established clinical faculty who require additional training in basic or translational research in order to establish a translational research program. We will support one new candidate in each year of the grant at a level of $87,500 per year for two years ($175,000 total) for each award. $75,000 per year will be provided by matching funds from the UNMC Eppley Cancer Center, and $100,000 will be provided by the SPORE program, so that up to $175,000 total per year is available for this program. Individuals in this program are required to commit substantial effort (a minimum of 40%, and higher percent efforts are strongly encouraged and will receive preferential selection) to SPORE related translational research. Funds can be used for salaries or any other aspect of development (research costs) that are deemed necessary for the candidate to succeed in establishing a translational pancreatic cancer research program. The candidate is required to submit an NIH G or R series grant application during the second year of the award, that is primarily focused on pancreatic cancer research.
| Nimmakayala, Rama Krishna; Batra, Surinder K; Ponnusamy, Moorthy P (2018) Unraveling the journey of cancer stem cells from origin to metastasis. Biochim Biophys Acta Rev Cancer 1871:50-63 |
| Aithal, Abhijit; Rauth, Sanchita; Kshirsagar, Prakash et al. (2018) MUC16 as a novel target for cancer therapy. Expert Opin Ther Targets 22:675-686 |
| Barkeer, Srikanth; Chugh, Seema; Batra, Surinder K et al. (2018) Glycosylation of Cancer Stem Cells: Function in Stemness, Tumorigenesis, and Metastasis. Neoplasia 20:813-825 |
| Naramura, Mayumi; Natarajan, Amarnath (2018) Mouse Pancreatic Tumor Model Independent of Tumor Suppressor Gene Inactivation. Pancreas 47:e27-e29 |
| Contreras, Jacob I; Robb, Caroline M; King, Hannah M et al. (2018) Chemical Genetic Screens Identify Kinase Inhibitor Combinations that Target Anti-Apoptotic Proteins for Cancer Therapy. ACS Chem Biol 13:1148-1152 |
| Wang, Gang; Biswas, Anup K; Ma, Wanchao et al. (2018) Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat Med 24:770-781 |
| Murthy, Divya; Attri, Kuldeep S; Singh, Pankaj K (2018) Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics. Front Physiol 9:335 |
| Barkeer, Srikanth; Chugh, Seema; Karmakar, Saswati et al. (2018) Novel role of O-glycosyltransferases GALNT3 and B3GNT3 in the self-renewal of pancreatic cancer stem cells. BMC Cancer 18:1157 |
| Rana, Sandeep; Sonawane, Yogesh A; Taylor, Margaret A et al. (2018) Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy. Bioorg Med Chem Lett 28:3736-3740 |
| Roy, Sohini; Bag, Arup K; Dutta, Samikshan et al. (2018) Macrophage-Derived Neuropilin-2 Exhibits Novel Tumor-Promoting Functions. Cancer Res 78:5600-5617 |
Showing the most recent 10 out of 191 publications
